Abbvie Inc
NYSE: ABBV
$200.45
-$0.76 (-0.4%)
Real Time Data Delayed 15 Min.
ABBV Articles
courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull market is...
Published:
Last Updated:
While it seems everything is fully priced, the good news for investors is that there is still a plethora of stocks that are cheaper than the overall S&P 500.
Published:
Last Updated:
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Albermarle, Blue Apron, Box, Dish Network, GM, Transocean and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring with the exception of the Nasdaq. Crude oil backed off after posting a few days...
Published:
Last Updated:
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
Published:
Last Updated:
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
Published:
Last Updated:
AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the report's top picks: AbbVie, Eli Lilly, Merck, and Shire.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated: